Literature DB >> 9485029

HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions.

M Vitale1, R Rezzani, L Rodella, G Zauli, P Grigolato, M Cadei, D J Hicklin, S Ferrone.   

Abstract

Five specimens of normal mammary tissue and 53 primary breast carcinoma lesions were tested for expression of HLA antigens and components of the antigen-processing machinery by immunohistochemical staining. The expression of transporter associated with antigen processing (TAP) 1, TAP2, and HLA class I antigens in breast carcinoma lesions was significantly associated with tumor grading. Like normal mammary tissue, the 16 low-grade (G1) breast carcinoma lesions showed strong staining for TAP1, TAP2, and HLA class I antigens. In contrast, only 12 (32%) of 37 high-grade (G2 and G3) breast carcinoma lesions displayed the normal staining pattern. In 14 (38%) of 37 high-grade lesions, HLA class I antigen down-regulation was observed without loss of low molecular mass polypeptide and/or TAP staining. Congruent down-regulation of HLA class I antigen and TAP1 or TAP2 was found in 8 (22%) of 37 high-grade lesions. Complete loss of HLA class I antigens, TAP1, and TAP2 was observed in 3 (8%) of 37 high-grade lesions. No lesion was negative for TAP1 and/or TAP2 staining while positive for HLA class I antigen staining. These data demonstrate an association of HLA class I antigen and TAP down-regulation with tumor progression in breast carcinoma. This association suggests that loss of HLA and/or TAP may represent an escape from the host's immune pressure or may reflect the accumulation of abnormalities associated with neoplastic progression. This accumulation of defects in antigen processing and presentation may in turn be responsible for reduced recognition of malignant cells by putative clinically relevant tumor-specific T cells.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9485029

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  43 in total

1.  Expression of antigen processing and presenting molecules in brain metastasis of breast cancer.

Authors:  Yan Liu; Yoshihiro Komohara; Natalie Domenick; Masasuke Ohno; Maki Ikeura; Ronald L Hamilton; Craig Horbinski; Xinhui Wang; Soldano Ferrone; Hideho Okada
Journal:  Cancer Immunol Immunother       Date:  2011-11-08       Impact factor: 6.968

2.  Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake.

Authors:  Markus Loeffler; Jörg A Krüger; Andreas G Niethammer; Ralph A Reisfeld
Journal:  J Clin Invest       Date:  2006-06-22       Impact factor: 14.808

3.  The role of KIR genes and their cognate HLA class I ligands in childhood acute lymphoblastic leukemia.

Authors:  Adam J de Smith; Kyle M Walsh; Martha B Ladner; Siming Zhang; Carmen Xiao; Franziska Cohen; Theodore B Moore; Anand P Chokkalingam; Catherine Metayer; Patricia A Buffler; Elizabeth A Trachtenberg; Joseph L Wiemels
Journal:  Blood       Date:  2014-02-11       Impact factor: 22.113

4.  Cytosolic Processing Governs TAP-Independent Presentation of a Critical Melanoma Antigen.

Authors:  Nathalie Vigneron; Violette Ferrari; Benoît J Van den Eynde; Peter Cresswell; Ralf M Leonhardt
Journal:  J Immunol       Date:  2018-08-22       Impact factor: 5.422

Review 5.  The role of cytotoxic T-lymphocytes in the prevention and immune surveillance of tumors--lessons from normal and immunodeficient mice.

Authors:  I M Svane; M Boesen; A M Engel
Journal:  Med Oncol       Date:  1999-12       Impact factor: 3.064

6.  Association of CD8+ T cell infiltration in oesophageal carcinoma lesions with human leucocyte antigen (HLA) class I antigen expression and survival.

Authors:  T Tsuchikawa; H Ikeda; Y Cho; M Miyamoto; T Shichinohe; S Hirano; S Kondo
Journal:  Clin Exp Immunol       Date:  2011-02-24       Impact factor: 4.330

7.  Tumor-associated antigen profiling in breast and ovarian cancer: mRNA, protein or T cell recognition?

Authors:  Simone Kayser; Iris Watermann; Christine Rentzsch; Toni Weinschenk; Diethelm Wallwiener; Brigitte Gückel
Journal:  J Cancer Res Clin Oncol       Date:  2003-06-26       Impact factor: 4.553

8.  Immunocytochemical demonstration of down regulation of HLA class-I molecule expression in human metastatic breast carcinoma.

Authors:  Masanao Saio; Matt Teicher; Gaynor Campbell; Helen Feiner; Yara Delgado; Alan B Frey
Journal:  Clin Exp Metastasis       Date:  2004       Impact factor: 5.150

9.  Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients.

Authors:  Pedro A Andrade Filho; Andrés López-Albaitero; William Gooding; Robert L Ferris
Journal:  J Immunother       Date:  2010-01       Impact factor: 4.456

10.  Beta2-microglobulin signaling blockade inhibited androgen receptor axis and caused apoptosis in human prostate cancer cells.

Authors:  Wen-Chin Huang; Jonathan J Havel; Haiyen E Zhau; Wei Ping Qian; Hui-Wen Lue; Chia-Yi Chu; Takeo Nomura; Leland W K Chung
Journal:  Clin Cancer Res       Date:  2008-09-01       Impact factor: 12.531

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.